1-Isopropoxy-3-isopropylamino-propan-2-ol | 73313-29-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Isopropoxy-3-isopropylamino-propan-2-ol
• 英文别名: 1-(Propan-2-ylamino)-3-propan-2-yloxypropan-2-ol
• CAS: 73313-29-8
• 化学式: C₉H₂₁NO₂
• 分子量: 175.271
• InChiKey: DDIJCZMFBTXZIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丙基缩水甘油醚 、 异丙胺 以 various solvent(s) 为溶剂， 反应 20.0h， 生成 1-Isopropoxy-3-isopropylamino-propan-2-ol
  参考文献：
  名称：

  新型脂肪族肟醚的合成及β-肾上腺素的阻断活性。

  摘要：

  合成了新的β-肾上腺素能阻滞剂，其中大多数不含芳香核。它们衍生自烷基氨基-脂族肟醚或烷基氨基-脂族醚。其中最活跃的是O- [3-（叔丁基氨基）-2-羟丙基]乙酰肟（8;气管pA2 = 7.65）和1-异丁氧基-3-（叔丁基氨基）-2-丙醇（15;气管pA2 = 7.49），两者都显示出支气管选择性（β2 /β1比约为15）。讨论了芳香核在这类化合物中的作用和重要性。

  DOI：

  10.1021/jm00180a007

文献信息

• [EN] COMPOUNDS FOR TAU PROTEIN DEGRADATION<br/>[FR] COMPOSÉS POUR LA DÉGRADATION DE LA PROTÉINE TAU
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2019014429A1

  公开（公告）日：2019-01-17

  Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

  本文提供了一种双功能化合物，可以结合tau蛋白和/或促进定向泛素化以降解tau蛋白。具体来说，提供了可以结合tau蛋白的化合物，tau蛋白的聚集与多种神经退行性疾病（例如tau病变）有关，并且可以通过招募E3泛素连接酶（例如Cereblon）促进其降解，后者可以泛素化tau蛋白，标记其进行蛋白酶体降解。还提供了双功能化合物的放射标记形式、包含双功能化合物的药物组合物、检测和/或诊断神经疾病的方法、检测和/或诊断tau蛋白的病理性聚集的方法（例如在中枢神经系统中）、治疗和/或预防神经疾病的方法，以及通过给予本文描述的化合物或组合物在受试者中促进E3泛素连接酶活性降解tau蛋白的方法。
• Merged ion channel modulating compounds and Uses Thereof
  申请人：Choi Lewis S.L.

  公开号：US20090088464A1

  公开（公告）日：2009-04-02

  Merged compounds of ion channel modulating compounds, including, for example, merged compounds of the ion channel modulating compound of the following formula: (I) are described herein, as well as methods of making and using such merged compounds and pharmaceutical compositions containing such merged compounds.

  本文描述了离子通道调节化合物的合并化合物，包括以下式子的离子通道调节化合物的合并化合物：（I），以及制备和使用这种合并化合物的方法和含有这种合并化合物的药物组合物。
• LECLERC G.; BIETH N.; SCHWARTZ J., J. MED. CHEM., 1980, 23, NO 6, 620-624
  作者：LECLERC G.、 BIETH N.、 SCHWARTZ J.

  DOI：——

  日期：——
• Molecularly Well-defined Antibiofouling and Polyionic Coatings
  申请人：ACatechol, Inc.

  公开号：US20210017400A1

  公开（公告）日：2021-01-21

  The present application discloses molecularly well-defined antibiofouling and polyionic coatings, materials and methods of use.
• COMPOUNDS FOR TAU PROTEIN DEGRADATION
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20210154184A1

  公开（公告）日：2021-05-27

  Provided herein are bifunctional compounds that bind tau protein and/or promote targeted ubiquitination for the degradation of tau protein. In particular, provided are compounds that can bind tau protein, a protein whose aggregation is implicated in a variety of neurodegenerative disease (e.g., tauopathies), and can promote its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon), which can ubiquitinate tau protein, marking it for proteasomal degradation. Also provided are radiolabeled forms of the bifunctional compounds, pharmaceutical compositions comprising the bifunctional compounds, methods of detecting and/or diagnosing neurological disorders, methods of detecting and/or diagnosing pathological aggregation of tau protein (e.g., in the central nervous system), methods of treating and/or preventing neurological disorders, and methods of promoting the degradation of tau protein by E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.